Featured Research

from universities, journals, and other organizations

Epstein-Barr Virus Contributes To Burkitt's Lymphoma

Date:
November 20, 2003
Source:
University Of Wisconsin-Madison
Summary:
Most people may associate Epstein-Barr virus with infectious mononucleosis, but the tumor virus also has been implicated in at least five kinds of human cancer. The cancers include Burkitt's lymphoma--a malignancy endemic in African children--lymphomas in AIDS patients and one half of all Hodgkin's disease cases.

MADISON - Most people may associate Epstein-Barr virus with infectious mononucleosis, but the tumor virus also has been implicated in at least five kinds of human cancer. The cancers include Burkitt's lymphoma--a malignancy endemic in African children--lymphomas in AIDS patients and one half of all Hodgkin's disease cases.

Related Articles


In the Nov. 5, 2003, Proceedings of the National Academy of Sciences (PNAS) online, University of Wisconsin Medical School researchers report that Epstein-Barr virus (EBV) does, in fact, contribute directly to the survival of Burkitt's lymphoma tumors. By elucidating the exact mechanism involved in maintenance of the tumors, the researchers open the door to the development of effective, targeted therapies for all EBV-associated tumors.

Tumor viruses-such as human papilloma virus, hepatitis B virus and EBV--are responsible for 15 percent of all cancers in humans. The viruses combine with acquired genetic mutations to produce disease. While EBV lives unnoticed in as many as 95 percent of all humans, it also produces cancers that kill nearly 100,000 people around the world each year.

There are two ways to prevent tumor viruses from doing damage, according to Bill Sugden, PhD, professor of oncology at the McArdle Laboratory for Cancer Research. One is to develop a vaccine that triggers immune responses that neutralize the virus; the other is to cripple viral gene products that maintain cells as tumors.

"If you can find viral gene products that contribute not just to creating the tumor but also to maintaining it, you can conceivably destroy those gene products--and kill the tumor--without harming other tissues," says Sugden, the senior author on the PNAS paper who has worked on EBV for 30 years.

Sugden and lead author Greg Kennedy, MD, PhD, a surgery resident at UW Hospital and Clinics, and former post-doctoral fellow Jun Komano, PhD, examined the precise way in which EBV affects B cells that evolve to be tumors. Under normal conditions, B cells mount responses to invading organisms by making protective antibodies and then dying.

But with Burkitt's lymphoma, the system breaks down. "Burkitt's lymphoma is an aggressive B cell malignancy characterized by rapid cell proliferation that can be fatal within months if not treated immediately," says Sugden. The standard treatment is chemotherapy, which can destroy healthy as well as cancerous cells.

The Wisconsin researchers focused on one protein expressed by EBV and found in all EBV-related tumors-called Epstein-Barr nuclear antigen 1 (EBNA-1). "We and others had learned that not only is this protein required for the viral DNA to be replicated in cells, but it does so by binding to specific sites on the viral DNA," explains Sugden.

Almost 10 years ago, Sugden and his colleagues made a derivative of EBNA-1, which inhibits the real protein. When the derivative binds to its site on the EBV DNA, it prevents EBNA-1 from doing so, interrupting its functioning.

In the current experiments, begun five years ago, the scientists introduced the derivative into three kinds of B cells-EBV-infected Burkitt's lymphoma cells, normal EBV-infected cells and uninfected cells. They found that in all cells containing EBV, the derivative prevented the cells from proliferating--and unexpectedly induced them to die.

"In effect, EBNA-1 rescues B cells from their programmed death, and allows the cells to continue to proliferate," says Sugden. "In children destined to develop Burkitt's lymphoma, multiple events must occur in addition to infection with EBV. But the continued functioning of EBNA-1 is pivotal to the survival of these tumor cells."

An obvious approach to preventing the cell proliferation is inhibiting EBNA-1 from doing its job. "My hope is that scientists can now develop small molecules that carry out the same function as the EBNA-1 inhibitor we've made in the laboratory, but in a way that can be delivered readily to the tumor cells in patients," Sugden says. "Such therapy would induce programmed cell death in Burkitt's lymphoma."

It's reasonable to expect, he says, that a small molecule could be designed to attach to a specific location on EBNA-1 to keep it from functioning, without disturbing any other human proteins. "Finding such a therapy--one with no or minimal side effects--is our goal," says Sugden. "Tumor viruses that encode proteins not found in normal cells provide this unique possibility."

The UW cancer researcher will apply to the Grand Challenges in Global Health, which supports research addressing major health problems prevalent in Africa, for funding for more research.

"In addition to helping patients with Burkitt's lymphoma and Hodgkin's disease, treatment could help people with suppressed immune systems, who also are susceptible to B cell lymphomas," adds Sugden. The latter group includes bone marrow transplant, kidney transplant and AIDS patients.


Story Source:

The above story is based on materials provided by University Of Wisconsin-Madison. Note: Materials may be edited for content and length.


Cite This Page:

University Of Wisconsin-Madison. "Epstein-Barr Virus Contributes To Burkitt's Lymphoma." ScienceDaily. ScienceDaily, 20 November 2003. <www.sciencedaily.com/releases/2003/11/031119081205.htm>.
University Of Wisconsin-Madison. (2003, November 20). Epstein-Barr Virus Contributes To Burkitt's Lymphoma. ScienceDaily. Retrieved November 24, 2014 from www.sciencedaily.com/releases/2003/11/031119081205.htm
University Of Wisconsin-Madison. "Epstein-Barr Virus Contributes To Burkitt's Lymphoma." ScienceDaily. www.sciencedaily.com/releases/2003/11/031119081205.htm (accessed November 24, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, November 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Winter Can Cause Depression — Here's How To Combat It

Winter Can Cause Depression — Here's How To Combat It

Newsy (Nov. 23, 2014) Millions of American suffer from seasonal depression every year. It can lead to adverse health effects, but there are ways to ease symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com
WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins